PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
No Data
No Data available this quarter, please select a different quarter.
2.36
Higher net debt at 1.1-1.25x Biotechnology median of 2.08. John Neff would demand higher growth rates to justify this leverage premium.
-10661.81
Negative coverage while Biotechnology median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
5.65
Current ratio 1.25-1.5x Biotechnology median of 4.27. Philip Fisher would check if strong liquidity supports growth investments.
No Data
No Data available this quarter, please select a different quarter.